[Skip to Content]
[Skip to Content Landing]
Views 471
Citations 0
Invited Commentary
August 8, 2019

Factors to Consider When Contemplating Posttreatment Surveillance for Survivors of HPV–Associated Oropharyngeal Squamous Cell Carcinoma

Author Affiliations
  • 1Department of Otolaryngology–Head and Neck Surgery, Johns Hopkins School of Medicine, Baltimore, Maryland
JAMA Otolaryngol Head Neck Surg. Published online August 8, 2019. doi:10.1001/jamaoto.2019.1976

In this issue of JAMA Otolaryngology–Head & Neck Surgery, Masroor at al1 explore the outcomes associated with adherence to the current National Comprehensive Cancer Network (NCCN) posttreatment surveillance recommendations for human papillomavirus–associated oropharyngeal squamous cell carcinoma (HPV-associated OPSCC).2 Recognition of the favorable prognosis of HPV-associated OPSCC has led to the issue of whether the current NCCN-guided surveillance recommendations are appropriate for survivors of HPV-associated OPSCC. The goals of a regular surveillance schedule are to identify cancer recurrence and sequelae of therapy. To our knowledge, no study to date has evaluated the benefit of a surveillance schedule specific to HPV-associated OPSCC.